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IT'S A WONDERFUL GENOME: THE
WRITTEN-DESCRIPTION REQUIREMENT
PROTECTS THE HUMAN GENOME FROM
OVERLY-BROAD PATENTS1
EMANUEL VACCHIANO*

INTRODUCTION

George Bailey of Bedford Falls, New York, made it to college
after all!2 In fact, Doctor Bailey embarked on a great adventure,
joining thousands of others who are crossing a vast, unknown sea
attempting to discover its hidden secrets which may reveal the
cures to many of today's most deadly diseases.3
Fortunately,
George did not leave Bedford Falls for his adventure. For this
adventure is the Human Genome Project and the modern-day
explorers are scientists like Dr. Bailey, who received his Ph.D.
from the State University and set up a research lab in Bedford
1. After submission of this Comment for publication, the United States
Patent & Trademark Office (PTO) issued interim guidelines for examination of
patent applications under the written description requirement. Request for
Comments on Interim Guidelines for Examination of Patent Applications
Under the 35 U.S.C. § 112,
1 "Written Description" Requirement, 63 Fed.
Reg. 32,639 (1998). Additionally, on October 6, 1998, the PTO issued U.S.
Patent No. 5,817,479 which some claim is the first EST patent. Young et al.,
U.S. Patent No. 5,817,479. See Incyte Pharma Gets Patent On Human Kinase
Genes, Dow Jones News Service, Nov. 4, 1998 (discussing Incyte's
announcement that it had obtained a patent covering expressed sequence
tags). But see Patent on Gene Fragments Sends Researchersa Mixed Message,
396 NATURE 499, 499 (1998) (discussing the position of the PTO that this is
not an EST patent).
* J.D. Candidate, Jan. 2000. Special thanks are due to Donald Reynolds,
Dr. Patrick Halloran, and Daniel Boehnen for their critical reviews of drafts of
this Comment.
2. See IT'S A WONDERFUL LIFE (RKO and Liberty Films 1946) [hereinafter
WONDERFUL LIFE] (focusing on the life of a fictional generous and kind person,
George Bailey). The Wonderful Life movie does not involve a Human Genome
Project as discussed in this Comment. The author uses some of the characters
and themes from the movie to create a more enjoyable reading experience.
3. See generally Shannon Brownlee et al., Tinkering with Destiny, U.S.
NEWS & WORLD REP., Aug. 22, 1994, at 59 (discussing the implications of the
discovery of the BRCA1 breast cancer susceptability gene and future genomic
research on cancer treatment and diagnosis); Philip Elmer-Dewitt, The
Genetic Revolution, TIME, Jan. 17, 1994, at 46 (discussing the human genome
project and the practical implications of human genome discoveries).
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Falls to unmask the secrets of human life by using the power of
recombinant DNA technologies. 4
In 1991, based on results of human genome research, the
National Institutes of Health (NIH) announced that it planned to
file patents on small, incomplete sequences of genes called
"expressed sequence tags" (ESTs), derived from the human
genome.' A high-profile international debate ensued.' Although
many patents had issued on deoxyribonecleic acid (DNA) segments
from the human genome which encoded proteins, this was the first
time anyone attempted to obtain a patent on thousands of
segments of the human genome which did not encode entire
functional proteins and which were obtained by a routine masssequencing method.7
The NIH eventually abandoned these
applications in the face of PTO rejection.8 This seemed to establish
precedent that such DNA fragments were unpatentable. However,
several small biotechnology (biotech) companies resumed the effort
by applying for patents on thousands of ESTs they had isolated.9
4. See Lee Rowen et al., Sequencing the Human Genome, 278 SCIENCE
605, 605-607 (1997) (discussing the current status and future challenges of the
human genome project); G. Kenneth Smith & Denise M. Kettelberger, Patents
and the Human Genome Project, 22 AIPLA Q. J. 27, 28-46 (1994) (discussing
the history and technologies of the human genome project); see also ElmerDewitt, supra note 3, at 48-49 (discussing briefly the goal of the human
genome project and Francis Collins, one of the scientists leading this project).
5. See, e.g., NIH Seeks Second ControversialGene Patent, REUTERS N. AM.
WIRE, Feb. 12, 1992, available in LEXIS, News Library, ARCNWS File
(reporting on a news conference in which officials at the NIH announced the
filing of a patent covering thousands of ESTs).
6. See Reid G. Adler, Genome Research: Fulfiling the Public'sExpectations
for Knowledge and Commercialization, 257 SCIENCE 908, 908-13 (1992)
(discussing issues related to patenting ESTs and discussing NIH's reasons for
filing patent applications covering ESTs); Thomas D. Kiley, Patents on
Random Complementary DNA Fragments?, 257 SCIENCE 915, 915-18 (1992)
(discussing problems related to patenting ESTs); see also Rebecca S.
Eisenberg, Genetics and the Law: The Ethical, Legal, and Social Implications
of Genetic Technology and Biomedical Ethics: Intellectual Property at the
Public-PrivateDivide: The Case of Large-Scale cDNA Sequencing, 3 U. CHI. L.
SCH. ROUNDTABLE 557, 558-59 (1996) [hereinafter Genetics and the Law]
(discussing the debate that ensued surrounding the NIH EST patent filings);
Paul M. Rowe, Patenting Genes, J. Craig Ventor and the Human Genome
Project, 1 MOLECULAR MED. TODAY 12, 13 (1995) and Smith & Kettelberger,
supra note 4, at 46-51 (discussing the debate regarding ESTs surrounding
NIHs initial filings).
7. See sources cited supra note 6 (discussing the debate concerning
whether ESTs are patentable).
8. See, e.g., Rebecca S. Eisenberg & Robert P. Merges, OpinionLetter as to
the Patentability of Certain Inventions Associated with the Identification of
Partial cDNA Sequences, 23 AIPLA Q.J. 1, 13-50 (1995) (detailing the
prosecution history of the NIH EST patent applications).
9. Genetics and the Law, supra note 6, at 558-59; Eliot Marshall, Patent
Office Faces 90-Year Backlog; Patent Applications for DNA Sequences, 272
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These patent applications have been pending for a considerable
period of time at the United States Patent and Trademark Office
(PTO), in part, because the PTO is overwhelmed by the number of
sequences in these applications, and until recently, was unsure
about the patentability of these DNA segments.' °
Recently, the PTO announced that ESTs are patentable
subject matter." This announcement stimulated a renewed uproar
in the international community of human genome researchers
concerning the patenting of ESTs." However, now that it appears
imminent that the PTO will award patents to ESTs, the debate
focuses on the scope of the claims the PTO should award in the
patents. 13
Hypothetically, one of the biotech companies involved in the
EST debate was founded by a Bedford Falls opportunist, Mr.
Potter, who founded Potter's Gene Bank, one of the first companies
to focus on creating a proprietary EST database. 4 Potter's Gene
Bank randomly sequenced thousands of ESTs and applied for
patents on all of them in hopes of controlling the fate of a major
portion of the human genome.
Unfortunately, George Bailey's small biotech company,
Bailey's ESTs and Genes (Bailey's), was slow in obtaining funding
and failed to isolate its first EST until after Potter's Gene Bank
isolated thousands. However, unlike Potter's Gene Bank, Bailey's
focused on using ESTs to find genes and gene patterns that are

SCIENCE 643, 643 (1996);

Dan Goodin, Gene Genie, RECORDER, Aug. 20, 1997,

at 1.
10. Bruce Lehman, Major Biotech Issues for the U.S. Patent and Trademark
Office, 33 CAL. W. L. REV. 49, 59-60 (1996). See also Marshall, supra note 9, at
643-44 (discussing the huge backlog of patent applications claiming DNA
sequences); James Coburn, PTO Hearings on Nucleic Acid Sequences, INTELL.
PROP. TODAY, June 1996, at 15, 15 (discussing the large amount of resources

necessary to examine pending "mega sequence" patent applications).
11. Dorothy Auth, Are ESTs Patentable?, 15 NATURE BIOTECH 911, 911
(1997); James Coburn, EST's and Partial Sequences: Repercussions for the

Biotech Client, INTELL. PROP. TODAY, Aug. 1997, at 7; Vincent Kiernan,
Furore in US Over Patents for 'Bit part' DNA, NEW SCIENTIST, Feb. 22, 1997,

at 11. See also Goodin, supra note 9, at 1 (discussing the debate that followed
the PTO announcement that ESTs are patentable subject matter).
12. See sources cited supra note 11 (discussing the concerns of the biotech
community regarding EST patents).
13. See sources cited supra note 9 (discussing the concerns of the biotech
community regarding the scope of EST patents).
14. See WONDERFUL LIFE, supra note 2. The author does not intend Mr.
Potter's shrewd company to represent any of the actual biotech companies that
focus on creating EST databases. However, there is a perception that some of
the biotech companies involved with large scale EST discovery are attempting
to obtain patents covering much more than their actual discoveries.
Eisenberg, supra note 6, at 560-61; John Carey et al., The Gene Kings, Bus.
WK., May 8, 1995, at 74.
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correlated with human disease, and applied for patents only after
a thorough characterization of the ESTs and genes. George Bailey
has become increasingly concerned about the announcement that
the PTO will award patents with broad claims for ESTs because he
knows that Potter's Gene Bank filed patent applications on ESTs
with broad claims. These broad claims cover Bailey's most
promising discovery, the Uncle Billy gene, a candidate gene for the
treatment of Alzheimer's disease. 5
This Comment focuses on the appropriate protection the PTO
should award for claims of patents that disclose ESTs and other
uncharacterized, partial segments of the human genome. Part I
provides a technical background relating to the human genome
and ESTs. Part II focuses on patent laws and the application of
these laws by courts to traditional inventions and to inventions
related to the human genome. Part III relies on the hypothetical
controversy in Bedford Falls and analyzes the effect of various
scopes of intellectual property protection of ESTs on the
development of efficacious medical products. In addition, Part III
analyzes recent decisions by the Court of Appeals for the Federal
Circuit (CAFC) involving patents on human genes and attempts to
predict the scope of protection the CAFC will uphold for patents
relating to ESTs and other fragments of the human genome.
Based on this analysis, Part IV proposes minimum requirements
that the PTO should adopt in granting patents to DNA segments
derived from the human genome, such as ESTs, and suggests that
the PTO should award a narrow scope of protection for these
segments. Part IV then recommends that Congress, the PTO, and
the biotech community consider implementing a new patent
category for uncharacterized human DNA segments, such as
ESTs, with a reduced term and a diminished examination process.
I.

THE HUMAN GENOME, GENES AND ESTs

The human genome is the entire set of DNA found in virtually
every cell of the human body. 6 The human genome is organized
into a series of chromosomes, each of which is composed of one
continuous molecule of DNA that is arranged into interconnected
functional segments of DNA. 7 The DNA of a segment consists of a
sequential arrangement (called a DNA sequence) of four
nucleotides of unspecified length and function.5
15. See WONDERFUL LIFE, supra note 2 (involving the forgetful fictional
character, Uncle Billy).
16. BENJAMIN LEWIN, GENES V 657 (Oxford Univ.) (1994).

17. Id. Human genome segments that are not genes provide a variety of
functions. Id. at 749. For example, some segments are believed to be
important for the structural integrity of the chromosome. Id. at 751-52.
18. Id. at 87. The four types of nucleotides in DNA are adenosine,
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A small proportion of the DNA segments found on
chromosomes, called genes, contain nucleotide sequences that
have the capacity to direct the synthesis of proteins with specific
amino acid sequences using enzymes found within the cell through
a ribonucleic acid (RNA) intermediate. 9 Proteins carry out most of
the processes of a cell.2° Since only a specific subset of the genes in
the human genome is expressed by a particular cell, cells of the
body are capable of very specialized functions.
Scientists use
modern techniques making it possible to work backward and
direct the synthesis of DNA from an RNA molecule.2 A DNA
segment synthesized in this manner is called a complimentary
DNA (cDNA).u
In the mid 1980s, the U.S. government, joined by other
governments around the world, organized an international project,
called the Human Genome Project, with the goal of sequencing all
three billion nucleotides of the human genome. 4 Separate from
the Human Genome Project, scientists in industry and academia
analyzed the human genome by focusing on specific DNA
segments derived from the human genome, such as expressed
genes, in order to more quickly discover those genes likely to have
clinical or commercial utility."
In 1991, Craig Ventor of the NIH utilized a non-traditional
approach to rapidly obtain large amounts of meaningful
information concerning the human genome. 2' His method focused
on obtaining partial nucleotide sequence information from

guanidine, thymidine, and cytidine.

Id.

Several CAFC opinions include

background information regarding recombinant DNA technology. Amgen Inc.
v. Chugai Pharmaceutical Co., 927 F.2d 1200, 1203 (Fed. Cir. 1991), cert.
denied, 502 U.S. 856 (1991); In re O'Farrell, 853 F.2d 894, 895-99 (Fed. Cir.
1988).
19. See LEWIN, supra note 16, at 163-64. RNA is similar in structure to
DNA in that it is a sequentially arranged segment of one of four nucleotides.
Id. at 87. However, RNA is composed of the nucleotide uridine instead of the
nucleotide thymidine, which is found in DNA. Id. Furthermore, RNA exists
as a single-strand of nucleic acid, unlike DNA, which exists in a double
stranded helical arrangement. Id. at 109, 163-64.
20. Id.
21. Id. at 163-64.
22. Id. at 641.
23. Id.
24. See sources cited supra note 3 (discussing the human genome project).
Today, scientists have begun the final phase of that project, the actual
sequencing of the DNA. Rowen et al., supra note 4, at 607.
25. See, e.g., Mark D. Adams et al., Complementary DNA Sequencing:
Expressed Sequence Tags and Human Genome Project, 252 SCIENCE 1651,
1651 (1991) (describing the general technique for isolating ESTs by utilizing
RNA of expressed genes).
26. Id. at 1652-56.
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cDNAs."7 He called these2 8partial nucleotide sequences "expressed
sequence tags" or "ESTs."
Although ESTs per se do not define functional genes or
proteins, they are useful because they provide information
regarding functional, full-length genes and they are a powerful
tool for isolating these genes.2 9 For example, although ESTs are
quickly discovered using routine methods capable of being carried
out almost exclusively using robotics, ESTs provide structural
information regarding human genes, probes for discovering
complete genes, and markers for specific locations on the human
genome.30 Furthermore, ESTs provide an opportunity for rapidly
and inexpensively determining the extent to which a gene is
expressed in a given cell type or tissue."
Despite these utilities, ESTs have several inherent
limitations. 2 For example, in most cases they do not provide the
complete sequence of a cDNA.33 Therefore, since many genes are
composed in part of related or identical segments of DNA, a
scientist sometimes cannot unequivocally determine the gene from
which an EST is derived without further analysis." Furthermore,
ESTs are limited by the fact that methods employed to obtain
rapid sequence determinations are less accurate than the more

27. Id. at 1652.
28. Id. at 1651.
29. See, e.g., id. at 1655 (exemplifying the utility of ESTs in quickly
providing some structural information regarding genes and chromosomes).
30. Id. at 1652-56. See also Mark D. Adams et al., Rapid cDNA sequencing
(expressed sequence tags) from a directionally cloned human infant brain

cDNA library, 4 NATURE GENETICS 373 (1993) (exemplifying the use of ESTs
to obtain structural information regarding a gene and for identifying complete
genes); W. Guo et al., Genomic scanning for expressed sequences in Xp2l
identifies the glycerol kinase gene, 4 NATURE GENETICS 367 (1993)

(exemplifying the use of ESTs to obtain structural information regarding a
gene, and for identifying complete genes); Nickolas Papadopoulos et al.,
Mutation of a 'mutL' homolog in hereditary colon cancer, 263 SCIENCE 1625
(1994) (exemplifying the use of ESTs to discover full-length genes); MH
Polymeropoulos et al., Chromosomal distribution of 320 genes from a brain
cDNA library, 4 NATURE GENETICS 381 (1993) (exemplifying the use of ESTs

as markers for specific chromosomal locations).
31. Adams et al., supra note 25, at 1562-66 (identifying ESTs expressed in
the human brain).
32. See, e.g., id. (exemplifying that ESTs usually do not encompass entire
genes and do not provide any useful information and have a decreased

accuracy of DNA sequence determination); Leslie Roberts, Gambling on a
Shortcut to Genome Sequencing, 252 SCIENCE 1618, 1619 (1991) (discussing

limitations of ESTs related to the inability to discover all expressed genes by
ESTs and the inability of ESTs to provide information related to expression
control regions of genes).
33. E.g., Adams et al., supra note 25, at 1652-54.
34. Roberts, supra note 32, at 1618.
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Finally, the routine
careful and typical sequencing methods."
methods employed in discovering ESTs, although extremely
efficient, eliminate some of the creativity and inventiveness
traditionally employed in gene discovery.36
Following the initial discovery of ESTs by Craig Ventor, other
researchers and biotech companies discovered very large numbers
of ESTs and further developed EST technologies. 7 Several biotech
companies generate considerable revenue by licensing access to
their vast EST databases, which they protect as trade secrets, to
large pharmaceutical and diagnostics companies.& In addition,
several large public EST databases were established, in part, as a
result of corporate funding.3 9 At least one of these databases

35. Mark S. Boguski & Gregory D. Schuler, ESTablishing a Human
TranscriptMap, 10 NATURE GENETIcS 369, 371 (1995). Typically, sequencing
is done across both strands of a DNA segment using overlapping DNA
segments in order to allow a scientist to manually resolve redundancies that
arise. Rowen et al., supra note 4, at 607. Craig Ventor's group in their initial
study of ESTs determined the average DNA sequence accuracy for ESTs less
than four hundred base pairs in length to be 97.7%. Adams et al., supra note
25, at 1655. However, a more recent report, possibly based on improved
methods for EST determinations, suggests that the accuracy of DNA sequence
determinations for ESTs is 99%. Rowe, supra note 6, at 13. Even this level of
accuracy is far lower than the 99.9% accuracy required for DNA sequences
submitted as part of the human genome project. Rowen et al., supra note 4, at
607.
36. See Eisenberg & Merges, supra note 8, at 33 (discussing obviousness of
using the sequencing method utilized in the original EST publication to
discover other ESTs); Kiernan, supra note 11, at 11 (quoting renowned
molecular biologist Leroy Hood, "ESTs are the ultimate in non-thinking");
Roberts, supra note 32, at 1618 (quoting Craig Ventor describing ESTs as the
"ultimate in simplicity").
37. See sources cited supra note 9 (discussing EST initiatives by biotech
companies). Incyte Pharmaceuticals and Human Genome Sciences (HGS)
have filed patent applications apparently covering hundreds of thousands of
ESTs. Genetics and the Law, supra note 6, at 563; Goodin, supra note 9, at 1.
Incytes database reportedly now contains 2.5 million ESTs representing
approximately 100,000 distinct human genes. Incyte PharmaceuticalsHome
Page, LifSeq® database description (visited Apr. 4, 1998) <http://www.incyte.c
om/products/lifeseq.html> [hereinafter LifSeq].
38. Genetics and the Law, supra note 6, at 566-69.
39. Id. at 569-71 (describing Merck/Washington University EST initiative);
dbest: Database of Expressed Sequence Tags (visited Apr. 4,1998)
<http'//www.ncbi.nlm.nih.gov/dbEST> (containing EST sequences entered into
the public nucleotide sequence database Genbank, including those generated
by the Washington University program); UniGene (visited Apr. 4, 1998) <http:
//www.ncbi.nlm.nih.gov/schuler/unigene> (containing the National Center for
Bioinformatics EST database of transcript maps); Washington University
Merck & Co. EST ProjectHome Page (visited Apr. 4, 1998) <http://g
enome.wustl.edu/est/esthmpg.html> [hereinafter Washington University EST
Project Home Page] (containing information regarding Washington University
EST discovery program, partly funded by Merck & Co.).
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provides ESTs in pairs representing the ends of cDNAs, rather
than as individual ESTs arising from within a cDNA.4 ° Certain
databases are "functional" in that they provide more than
structural information regarding ESTs because they contain huge
amounts of data regarding relative expression patterns of
particular ESTs in various tissues, developmental states, and
diseases.4 Furthermore, scientists can utilize information in EST
databases as a first step in the discovery of single nucleotide
polymorphisms (SNPs)."
Single nucleotide polymorphisms are
single base pair differences that occur in the same chromosomal
location between different people that reveal differences between
larger segments of the genomes of these people.4"

40. See Boguski & Schuler, supra note 35, at 370 (indicating that the 3' and
5' ends of approximately 200,000 human cDNAs have been sequenced);
Washington University EST Project Home Page, supra note 39 (indicating in a
disclaimer that every effort was made to sequence both ends of the cDNA
clones).
41. See, e.g., LifSeq, supra note 37 (containing EST expression informations
from many different cells and tissues in normal and diseased tissue); The
Bodymap Anatomical Expression Database (visited Apr. 8, 1998) <http'/lwww.
imcb.osaka-u.ac.jp/bodymap> (containing data regarding gene expression in
various tissues). Several articles have been published which have identified
target genes by comparing EST information. M. A. Watson & T. P. Flemming,
Isolation of Differentially Expressed Sequence Tags from Human Breast
Cancer, 54 CANCER RES. 4598, 4598 (1994); Vasmatzis et al., Discovery of three
genes specifically expressed in human prostate by expressed sequence tag
database analysis, 95 PROC. NAT'L ACAD. SCi. U.S.A. 300, 300 (1998). Several
techniques have been developed which utilize ESTs to analyze gene expression
and find target genes. Philip Hieter & Mark Boguski, Functional Genomics:
It's All How You Read It, 278 SCIENCE 601, 601 (1997); Tom Strachan et al., A
New Dimension for the Human Genome Project: Towards Comprehensive
Expression Maps, 16 NATURE GENETICS 126, 126 (1997).
42. NCBI News, Unigene Collection, Aug. 1996 (visited Apr. 11, 1998)
<NCBI/Web/newstlr/Aug96.html>. The Unigene database can be used to find
polymorphisms by combining the data from many ESTs that appear to have
been generated from different cDNAs derived from the same gene. Id.
43. Francis S. Collins et al., Variations on a Theme: Cataloging Human
DNA Sequence Variation, 278 SCIENCE 1580, 1580-81 (1997).
Single
nucleotide polymorphisms act as markers for larger stretches of DNA, such as
specific alleles of a gene. Id. The capability of scientists to discover large
numbers of SNPs quickly and affordably provides information for new
proprietary databases and makes possible pharmacogenomic studies analyzing
the correlation of a person's specific genome to a drug response. Aris Persidis,
The Business of Pharmacogenomics, 16 NATURE BIOTECH 209, 209-10 (1998).
Spurred by a pharmacogenomic-related alliance of two companies based on a
large SNP database, scientists and biotech patent experts currently debate
whether SNPs should be patented. Elliot Marshall, Snipping Away at Genome
Patenting,277 SCIENCE 1752, 1752 (1997).
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II. PATENT LAW AND ITS APPLICATION TO HUMAN GENES

A. The Quid Pro Quo of PatentLaw
Our founding fathers recognized that advancement of
technology could be accelerated if the government granted
inventors the exclusive right to their inventions for a limited
period of time." As a result, Congress enacted a series of laws that
establish a quid pro quo between an inventor and the rest of
society.45 This quid pro quo gives an inventor the right to exclude
others from making, selling, or using his invention for a limited
period of time, while giving society a clear disclosure of the
invention.46
The intent is to promote the development of
technology by rewarding an inventor for his invention, while
providing society a disclosure of his invention which can be further
developed into other patentable inventions.47 Courts and the PTO
must uphold this purpose whenever they apply the patent laws to
a new discipline such as human genome research.4"
B. Recent Changes to U.S. Patent Laws

Congress recently changed U.S. patent laws, including those
relating to patent terms and the types of patent applications
available to inventors, in order to make U.S. patent law more
consistent with patent laws in other countries.4 9 For example, U.S.
Provisional patent applications are now available which do not
undergo an examination by the PTO, have a decreased cost, and
expire after one year.50 However, the U.S. patent system does not
contain a "diminished" type of patent that, unlike a provisional
application, issues as a patent but is reduced in term and

44. U.S. CONST. art.

I, § 8, cl. 8. See DONALD S. CHISUM, PATENTS: A

TREATISE ON THE LAW OF PATENTABILITY, at overview 1-15 (1995)

(describing

the historical development of patent law).
45. CHISUM, supra note 44, at 1-15.
46. Id.
47. Id.

48. See Adler, supra note 6, at 909 (discussing how biotech patent law is
being developed based on the established application of patent law to the
chemical arts); Rebecca S. Eisenberg, Structure and Function in Gene
Patenting, 15 NATURE GENETICS 125, 125 (1997) [hereinafter Structure and
Function in Gene Patenting] (discussing how patent law resolves new

controversies).
49. 35 U.S.C. § 111 (1995); 35 U.S.C. § 154 (1998); 37 C.F.R. § 1.9 (1997).
50. 35 U.S.C. § 111 (1995); 37 C.F.R. § 1.9 (1997); 37 C.F.R. § 1.16 (1997);
CHISUM, supra note 44, § 11.02[1]. The filing date of these applications can be
used as the filing date of a nonprovisional application if the nonprovisional
application is filed within 12 months of the filing of the provisional

application. Id.
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examination compared to a utility patent.51 This "diminished" type
of patent is available in other countries such as Australia.52
C. The Scope of Patent Protectionfor ESTs
1.

The Current Debate

The requirements for obtaining a patent for an invention can
be divided as follows: (i) determining whether the discovery falls
within one of the statutory categories; (ii) determining whether the
discovery has utility and possesses the level of novelty and
nonobviousness to justify being an invention; and (iii) determining
the form and level of disclosure needed to receive a patent.53 In the
past, various individuals and organizations interested in biotech
debated whether ESTs were patentable inventions, especially
when considering the utility requirement.5 Now that it appears
the PTO will award such patents, these same individuals and
organizations debate the limitations that the written-description
requirement found in 35 U.S.C. § 112 places on the scope of the
claims of these patents.55 The scope of the claims is important
because it determines, for example, whether an inventor can
exclude others from making or selling an entire protein-coding
DNA segment or gene that contains a patented EST. 56 The entire
51. Patents Act, 1990, § 52 (Austl.). The Australian petty patent has a six
year rather than 20 year term, involves a narrower prior art base, and
involves an accelerated examination. Id. In addition, the newly proposed
'Innovation' patent as a replacement for the current petty patent which would
provide accelerated patent protection for a reduced term at a lower cost for
inventions which meet a lowered innovation threshold. Australia to Consider
Second-Tier 'Innovation'Patent, 9 J. PROPRIETARY RTS. 28, 28 (1997).
52. See supra note 51 and accompanying text for a discussion of the
Australian petty patent and proposed Innovation patent.
53. See 35 U.S.C. § 101 (1975) (providing utility requirement and
patentable subject matter categories); 35 U.S.C. §102 (1975) (providing novelty
requirement); 35 U.S.C. § 103 (1975) (providing nonobvious subject matter
requirement); 35 U.S.C. § 112 (1975) (providing requirements of the

specification of the patent application including the best mode, enablement,
and written-description requirements, as well as the requirement for a claim
"particularly pointing out and distinctly claiming" the invention).
54. See sources cited supra note 6 (discussing the early debate which
focused on whether ESTs meet the utility requirement).
55. Auth, supra note 11, at 911-12; Goodin, supra note 9, at 2-3; Eisenberg
& Merges, supra note 8, at 37-51; Lynn Pasahow & Andrew Kumamoto,
Human Genome Project Raises PatentingIssues, NAT'L L. J., Oct. 20, 1997, at
C31, C32; Benjamin Thorner, Trading Patent Rights for Research Tools:

What's at Stake?, 15 NATURE BIOTECH 1024, 1025-26 (1997); Gail Dutton,
Genomic Intellectual Property, Patent Claims are Narrowing Based on
Genomic Data, GENETIC ENGINEERING NEWS, Feb. 15, 1998, at 20.
56. See sources cited supra note 55 (discussing the effects of a broad scope

of patent protection for EST patent disclosures). In addition, the written-
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protein-coding region is much more likely to be clinically useful
than the EST itself5 7
2.

The Written-DescriptionRequirement

The written-description requirement assures those skilled in
the art that the applicant was in full possession of the invention at
the time of filing the application." The requirement also functions
to assure the quid pro quo of patent law, namely, the availability
of the disclosure enables others to develop improvements on the
invention and to practice the invention after the patent expires. 59
description requirement mandates that a patent application contain an
enabling disclosure, at least one claim "particularly pointing out and distinctly
claiming" the invention, and reveal the best mode of carrying out the
invention. 35 U.S.C. § 112 (1975). Because of the overlapping nature of the
enablement, written-description, and "precise claim" requirements, courts
sometimes confuse these requirements. See CHISUM, supra note 44, § 8.03[2].
In fact, Justice Markey argues that the written-description requirement
should not be a separate requirement because it is redundant and confusing.
In re Barker, 559 F.2d 588, 594-95 (C.C.P.A. 1977), cert. denied, 434 U.S. 1064,
(1978) (Markey, J., dissenting); CHISUM, supra note 44, § 7.04[1][a][iv]. The
importance of these requirements is as follows: they define the scope of
protection against potential infringing parties, provide boundaries within
which other inventors cannot obtain patents, and establish that the applicant
is entitled to this scope of protection. Id. These requirements also address
many of the concerns that individuals and groups with interests in biotech
raise with respect to granting patents to ESTs. See supra note 55 for articles
that discuss these requirements in the context of EST patent applications.
The specification of a patent application must contain at least one claim
"particularly pointing out and distinctly claiming the subject matter which the
applicant regards as his invention." 35 U.S.C. § 112 (1975). The claims define
the scope of the invention; their purpose is in determining whether the
invention meets the requirements for patentability, and in determining
infringement. CHISUM, supra note 44, § 8.01. The transitional phrases
"comprising," "consisting of," and "consisting essentially of' have very different
and important meanings regarding the scope of patent claims.
U.S.
DEPARTMENT OF COMMERCE, PATENT AND TRADEMARK OFFICE, MANUAL OF

PATENT EXAMINING PROCEDURE § 2111.03 (6th ed. 1996) [hereinafter
M.P.E.P.]. The transition phrase "consisting of" excludes any element or step
not listed in the claim. Id. The phrase "consisting essentially of" limits the
claim to the listed elements or steps "and those that do not materially affect
the basic and novel characteristics of the claimed invention." Id. (emphasis in
original).
The term "comprising" is open-ended and does not exclude
additional elements or steps. Id. Therefore, a patent claim which reads "A
DNA fragment comprising the nucleotide sequence GGCGG" would include
any DNA sequence, including a 2000bp DNA sequence encoding a complete
protein, which includes the sequence GGCGG at some point in the sequence.
Auth, supra note 11, at 911.
57. See sources cited supra note 55 (discussing the effects of a broad scope
of patent protection for EST patent disclosures).
58. CHISUM, supra note 44, § 7.04; Lockwood v. American Airlines, 107 F.3d
1565, 1572 (Fed. Cir. 1997).
59. Id.
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The CAFC follows the precedent set by its predecessor, the Court
of Customs and Patent Appeals (CCPA), in holding that to meet
the written-description requirement an inventor must precisely
describe an invention by "words, structures, figures, 6diagrams,
0
formulas, etc., that fully set forth the claimed invention."
3.

The Written-DescriptionRequirement and DNA Segments

Recent CAFC decisions indicate that in order to meet the
written-description requirement for a claim to a gene, a
specification must recite the complete nucleotide sequence of that
gene.
In Fiers v. Revel, the CAFC held that a DNA encoding
beta-interferon was not adequately described by a patent unless
the patent disclosed the entire nucleotide sequence of that DNA.
The CAFC held that disclosure of a method for isolating a
fragment encoding beta-interferon did not meet the writtendescription requirement for a DNA encoding beta-interferon. 8 In
reaching its decision, the CAFC opined that to meet the written-

60. Lockwood, 107 F.3d 1565, 1572. In Lockwood, the Court held that a
computer entry system was not described by an earlier application which
failed to disclose some of the limitations of the later filed application. Id. In
Ruschig v. , an inventor sought to add a claim to a certain species of a
chemical compound during prosecution of a patent application. 379 F.2d 990,
991 (C.C.P.A. 1967). The original patent application described reagents

necessary to prepare the species and claimed a genus encompassing this
chemical species. Id. However, in affirming the PTO Board of Appeals
(Board) rejection of the species claim, the CCPA held that the claim to the
species was not allowable because the specification did not disclose the
compound as something the inventor invented. Id. at 995. See also CHISUM,
supra note 44, § 7.04 (discussing the written description requirement). In its
opinion the court stated that:
It is an old custom in the woods to mark trails by making blaze marks
on the trees. It is no help in finding a trail or in finding one's way
through the woods where the trails have disappeared-or have not yet
been made, which is more like the case here-to be confronted simply by
a large number of unmarked trees. Appellants are pointing to trees. We
are looking for blaze marks which single out particular trees. We see
none.
Ruschig, 379 F.2d at 994-95.
However, the CAFC holds that where a patent contains claims to a genus,
every species that falls within the genus need not be described in the patent.
Utter v. Hiraga, 845 F.2d 993, 998 (Fed. Cir. 1988). In Utter, the CAFC held
that a patent disclosure had a sufficient written description for a genus, even
though the claim covered some species that were patentably distinct from the
generic claim. Id. The patent applications in this interference were for scroll
compressors for air conditioners. Id. One species of the genera contained an
external pivot, which was not described in the patent for the genera. Id.
61. Regents of the University of California v. Eli Lilly, 119 F.3d 1559, 1567
(Fed. Cir. 1997); Fiers v. Revel, 984 F.2d 1164, 1170 (Fed. Cir. 1993).
62. Fiers, 984 F.2d at 1170.
63. Id. at 1169-71.
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description requirement, a DNA sequence must be defined
precisely "such as by structure, formula, chemical name, or
physical properties."'
Recently, in Regents of the University of California v. Eli

Lilly, the CAFC affirmed its position that the written description
of a claimed DNA segment requires a recitation of the DNA
sequence of the complete DNA segment.' In Regents, the CAFC
found that the written-description requirement was not met for a
claim to the human insulin cDNA, since the patent did not disclose
the DNA sequence of that cDNA, even though the patent disclosed
the amino acid sequence of human insulin.6 The court reasoned
that since a DNA segment is not obvious unless its sequence is
determined, the DNA segment is not described unless its sequence
is determined." Thus, the CAFC requires the disclosure of a
complete DNA sequence of a claimed DNA segment in order to
meet the written-description requirement for that DNA segment.'
64. Id. at 1171.
65. Regents, 119 F.3d at 1567.
66. Id. The patent disclosed the DNA sequence of the rat homologue and
the amino acid sequence of the human protein. Id. at 1562. The court also
held that the disclosure did not provide a sufficient written description for
generic claims to vertebrate and mammalian insulin cDNAs since it revealed
the structure of only one species. Id. at 1567-69.
67. Id. at 1567.
68. Another important requirement of biotech patent applications in
addition to the written-description requirement is the enablement
requirement. 35 U.S.C. § 112 (1975). To meet the enablement requirement, a
patent disclosure must teach one of ordinary skill in the art how to make and
use the invention. CHISUM, supra note 44, § 7.01. The essential question is
whether the scope of enablement is as broad as the scope of the claims. Id.
§ 7.03 [7].
However, a patent may be enabled even though some
experimentation is necessary. In re Wands, 858 F.2d 731, 737-38 (Fed. Cir.
1988). In Wands, the court provided several factors that are relevant in
determining whether undue experimentation is required. Id. at 731. These
factors include:
(1) the quantity of experimentation necessary, (2) the amount of
direction or guidance presented, (3) the presence or absence of working
examples, (4) the nature of the invention, (5) the state of the prior art,
(6) the relative skill of those in the art, (7) the predictability or
unpredictability of the art, and (8) the breadth of the claims.
Id. The court analyzed these factors and held that it would not require undue
experimentation for one of ordinary skill in the art to make the claimed
antibodies. Id. at 740. In claims to generic compounds, an inventor need not
disclose every species to meet the enablement requirement for the generic
compounds. CHISUM, supra note 44, at 7.03 [4]. Rather, a patent must
disclose a representative number of species within the genus. Id. In
Application of Angstadt, the court held that even in an unpredictable art
applicants do not have to disclose every species encompassed by their claims.
537 F.2d 498, 502-03 (C.C.P.A. 1976). Furthermore, courts hold that the
mention of representative compounds for generic claims may substitute for an
explicit description of generic claim language. In re Robins, 429 F.2d 452, 456-
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III. WHAT IS THE IDEAL SCOPE OF PATENT PROTECTION FOR ESTs?
This Part attempts to identify the ideal intellectual property
protection for ESTs and other DNA segments isolated from the
human genome. Section A considers the scope of protection that it
appears the PTO will award for EST patent claims and considers
the effects of a broad scope of protection on a hypothetical medical
product discovery. Section B further analyzes this medical product
discovery in order to define the objectives for an optimal scope of
protection for EST patents.
Section C compares various
intellectual property protection options for ESTs to determine the
best option. Section D considers the scope of protection that the
CAFC is likely to uphold and compares this to the ideal scope of
protection from a medical product development perspective.
Section E considers the written-description requirement, taking
into consideration several factual variables surrounding EST

57 (C.C.P.A. 1970).
The CAFC has also addressed the enablement requirement with respect to
biotech inventions. Genentech, Inc. v. Novo Nordisk A/S, Novo Nordisk or
North America, Inc., and Novo Nordisk Pharmaceuticals, Inc., 108 F.3d, 1361,
1363-68 (Fed. Cir. 1997); In re Deul, 51 F.3d 1552, 1556 (Fed. Cir. 1995);
Amgen, Inc. v. Chugai Pharmaceuticals Co., Ltd. and Genetics Institute, Inc.,
927 F.2d 1200, 1212-14 (Fed. Cir. 1991). The CAFC requires that a patent
contains an extensive characterization of a gene to enable broad claims
encompassing that gene and variants with similar properties. Amgen, 927
F.2d at 1213-14. See also Kenneth Chahine, Going Beyond the Native:
Protecting DNA and Protein Patents, 15 NATURE BIOTECH 183, 185 (1997)
(discussing the characterizations of a gene necessary to cover broad patent
claims encompassing variants of that gene). The CAFC has invalidated
several early patents to recombinant DNA discoveries that contained broad
claim language. Amgen, 927 F.2d at 1213-14; Genentech, 108 F.3d at 1366-68.
For example, in Amgen the CAFC held that a claim to every possible analog of
the human erythropoietin gene that encoded the erythropoietin protein was
not enabled by a disclosure that provided data from several analogs of the
gene. 927 F.2d at 1213-14. The Court held that a method for making more of
the specific analogs and structural requirements for the compounds with EPOlike activity was required. Id.
More recently, in Genentech, the CAFC held that a patent which disclosed
the DNA sequence of mature human growth hormone was not enabled for the
production of this protein through a fusion protein intermediary. 108 F.3d at
1366-68. The CAFC held that the patent specification did not enable the
production of mature growth hormone in this manner because this method of
production was only generally described in the specification, and the technique
had never successfully been used before the patent application was filed. Id.
at 1366.
In Deuel, the CAFC again indicated its reluctance to award broad claims to
recombinant DNA molecules. 51 F.3d at 1559. In this case, the court
questioned whether a patent was enabled where the claims were directed to
all of the nucleotide sequences that code for the native amino acid sequence of
the HBGF proteins, but the patent disclosed only the native sequence. Id. at
1560.
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discoveries. Section F considers whether the written-description
requirement is met for an EST DNA segment itself, considering
several technical limitations of ESTs. Finally, Section G considers
the optimal scope of protection for other inventions derived from
the human genome.
A. The PTO's Intent to Award ESTs a Broad Scope of Patent
Protection and the Effect of this Broad Scope on a Hypothetical
Medical ProductDiscovery
In recent scientific meetings, officials at the PTO indicated
that patent protection that, in effect, encompasses an entire cDNA
based on the disclosure of an EST, can be granted.69 To determine
the effect on medical breakthroughs of providing such broad
patent protection to ESTs, and to set objectives for optimal patent
protection of ESTs, consideration is given to a hypothetical series
of discoveries, starting with the discovery of an EST and
culminating in a medical breakthrough.7 °
We start by analyzing the key milestones in the isolation and
development of the Uncle Billy gene.7' First, Potter's Gene Bank
embarks on a large-scale EST discovery project by sequencing
thousands of ESTs.72
The company applies for broad patent
protection on the ESTs even though the only known information
regarding the ESTs, besides their nucleotide sequence, is their

69. See supra note 55 and accompanying text (discussing the announcement
by the PTO that patents to ESTs will be awarded). From the comments of
PTO officials, it appears that the PTO will allow claims that incorporate
"comprising" language in patents which disclose ESTs. Id. See supra note 56
for a discussion of the meaning of various claim terms. The comments of PTO
officials indicate that an acceptable claim in a patent containing an EST
disclosure might read: "A segment of DNA comprising the sequence..."
followed by the sequence of the EST. Auth, supra note 11, at 911-12; Pasahow
& Kumamoto, supra note 55, at C31.
The patent protection against
infringement for a claim with this verbiage covers any DNA sequence,
including the full-length gene, which contains the EST sequence. See supra
notes 55-56 for articles and accompanying text discussing the scope of
protection provided by DNA segment claims with "comprising" language.
70. Many of the discoveries in this hypothetical series are based on actual
discoveries.
These actual discoveries are referenced in the footnotes
associated with the description of the hypothetical discoveries in the text.
71. See supra note 15 and accompanying text for a reference describing the
"Uncle Billy" gene.
72. See supra notes 37 and 39 and accompanying text for a discussion of
private and public organizations that have embarked on large-scale EST
discovery projects. In the hypothetical discovery scenario, Potter's database
contains ESTs derived from cDNA libraries from a variety of organs,
individuals, and disease states. See supra note 41 and accompanying text for
a discussion of functional databases and the use of ESTs to discover target
genes.
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tissue of origin.73 Unknown to Potter's Gene Bank at the time of
filing their EST patent applications, one of the ESTs, C0292,
contains the sequence of a small segment of the Uncle Billy gene.
Second, Potter's Gene Bank enters into a lucrative licensing
agreement with Big Pharma Healthcare Inc. (Big Pharma).
Potter's Gene Bank grants Big Pharma access to its functional
EST database to75 identify candidate genes for cancer treatments
and diagnostics.
Third, Bailey's identifies two overlapping ESTs, BFHS3 and
BFHS1928, which together reveal the sequence of the entire
protein-coding region of the human Uncle Billy gene."6 Based on a
comparison of the expression of these ESTs in normal and
Alzheimer's disease-affected brains, Bailey's learns that the Uncle
Billy gene is expressed in the normal brain but not in the brains of
Alzheimer's patients.7 7 Based on an extensive characterization of
the Uncle Billy gene in many mammalian species, including
humans, Bailey's files a patent application claiming all
mammalian Uncle Billy genes, and subsequently is awarded a
patent with this broad claim scope. 8
73. See supra notes 5 and 9 and accompanying text for references and a
discussion of the large numbers of EST patent application filings, first from
the public and then from the private sector.
74. See Eisenberg, supra note 48, at 127-29 (discussing the discovery of the
leptin receptor, and the current dispute regarding patent rights to the gene
encoding that receptor, in light of the presence of another patent application to
the gene encoding a previously unknown isoform of that receptor, an EST in
the public domain containing part of the DNA encoding the receptor and the
likelihood of a patent application filed by a private company covering the
leptin receptor based on an EST disclosure); Judy Foreman, Research Teams
Race to Air Discovery of Gene Tied to Cancer, BOSTON GLOBE, Mar. 28, 1997,
at All (discussing the discovery of a new gene, P-TEN or MMAC1, by separate
groups who are each seeking patents). There is a possibility that a biotech
company has already applied for a patent on that gene using information from
ESTs. Id.
75. See supra note 38 and accompanying text for a discussion of the
licensing agreements that have been entered into between biotech companies
and large pharmaceutical companies for access to EST databases.
76. See Unigene, supra note 39 (indicating that some of the ESTs from
public databases overlap to yield an entire cDNA sequence); Lifseq, supra note
37 (indicating in LifeseqFL contains full length gene sequences which are
generated by assembling, inter alia, EST sequences).
77. See supra note 30 and accompanying text for a discussion of the use of
EST databases to discover target genes for specific diseases.
78. See also Regents of the Univ. of Cal. v. Eli Lilly, 119 F.3d 1559, 1567-69
(Fed. Cir. 1997) (discussing patent claims which attempted to cover all
vertebrate or all mammalian insulin cDNAs). In Regents, the court broadly
defined a type of characterization that would meet the written-description
requirement for an entire genus:
A description of a genus of cDNAs may be achieved by means of a
recitation of a representative number of cDNAs, defined by nucleotide
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Fourth, publication of the Uncle Billy gene sequence follows
the issuance of the U.S. patent. This allows Mr. Gower, a
researcher at New York University, to make a key discovery that
improves the efficacy of all forms of gene therapy.
Fifth, encouraged by the findings of Bailey's, Sam
Wainwright's Fortune 500 company Hee Haw Healthcare Inc. (Hee
Haw) signs a licensing agreement with Bailey's for the use of the
Uncle Billy gene for the treatment of Alzheimer's.' ° Hee Haw also
signs a licensing agreement with Mr. Gower for rights to use his
gene therapy discovery with the Uncle Billy gene.
Finally, Hee Haw licenses the rights to many other genes
from several other biotech companies for use on a diagnostic gene
chip."' This chip reveals the gene expression pattern of those
patients who will respond to gene therapy using the Uncle Billy
gene. 82
Soon after Hee Haw obtains encouraging results from clinical
trials using the Uncle Billy gene in combination with the
diagnostic gene chip, the PTO issues a patent to Potter's Gene
Bank for their C0292 EST with broad claims that encompass the
entire Uncle Billy gene.' Distraught, George Bailey heads for a
bridge.
B. Objectives for Optimal Protectionof ESTs
The most obvious observation from this hypothetical
discovery series is the danger of awarding overly broad patents
based on EST disclosures. This scenario illustrates that broad

sequence, falling within the scope of the genus or of a recitation of
structural features common to the members of the genus, which features
constitute a substantial portion of the genus.
Id. at 1569.
79. See WONDERFUL LIFE, supra note 2 (casting the apparent alcoholic
pharmacist Mr. Gower). Currently, in the United States, when patents are
issued the entire patent file, including the patent specification is open to the
public. 37 C.F.R. § 1.11 (1997). Furthermore, inventors can publish their
discoveries up to 1 year before filing an application and still retain their
patent rights on the discovery. 35 U.S.C. § 102 (1975).
80. See, e.g., Structure and Function in Gene Patenting, supra note 48, at
128 (discussing a similar agreement, reportedly worth $500,000, for
developing commercial products from a patented gene and its protein product).
81. See Marshall, supra note 43, at 1753 (discussing "poly 2000 chip" a
diagnostic medical tool of the future); Strachan et al., supra note 41, at 126-27
(discussing gene "chip" technologies, which allow the analysis of the
expression of thousands of genes simultaneously).
82. See supra note 81 and accompanying text for articles discussing gene
chips.
83. See supra note 55 and accompanying text for a discussion of the broad
scope of patent protection that the PTO appears prepared to award based on
EST disclosures.
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patents based on EST disclosures provide extensive control to
companies who merely determine the sequence of a small DNA
fragment in a routine mass-sequencing procedure while disclosing
little about the true nature, function, or utilization of the
associated gene. Such companies get the power to control the
development of the EST into a medical breakthrough without
significantly contributing to the achievement.
Another important observation this scenario reveals is that
the greatest value of ESTs may not lie in the individual ESTs, but
may lie in the synergism of EST data in functional EST
databases.84 Optimally then, patent protection awarded for ESTs
must promote the construction and expansion of EST databases.'
The hypothetical gene discovery scenario also reveals that it
is likely that medical breakthroughs which utilize human genome
discoveries, such as the Uncle Billy gene, depend on many other
technologies and discoveries. Therefore, it is likely that large
healthcare companies, like Hee Haw, will have to wade through a
complex web of intellectual property to license optimal
technologies and ultimately market human genome discoveries.86

84. See supra note 41 and accompanying text for a discussion of functional

EST databases. Arguably the most important and difficult discovery from a
scientific perspective in the determination and use of human genome
information is the determination of which genes or gene combinations might
be involved in disease progression from the huge number of genes and possible
gene combinations. Carey et al., supra note 14, at 74. According to Michael
Steinmetz, vice-president for clinical R&D at Hoffman-LaRoche, "Identifying
genes is only the beginning of a long, painful, and expensive process of drug
development." Id. Possibly the greatest value of ESTs is that they provide a
relatively inexpensive and- quick method for obtaining "snapshots" of gene
expression patterns for a given cell or tissue. See supra note 41 and
accompanying text for a discussion of functional EST databases.
By
comparing the pattern of gene expression from these "snapshots," candidate
diagnostic and pharmaceutical genes and gene combinations are revealed. See
generally Watson & Flemming, supra note 41, at 4598 (utilizing this strategy
to identify a candidate gene involved in breast cancer). This is one reason that
small genome companies have obtained large licensing agreements for access
to their huge EST libraries which contain EST gene expression "snapshots"
from many individuals for many tissue types and many disease states. Lifseq,
supra note 37. Drug discovery companies have paid large sums of money for
access to Incyte's databases. Genetics and the Law, supra note 6, at 568-69.
85. See supra notes 37, 39, and 41 and accompanying text for a discussion
of EST databases. Potter's Gene Bank is not dependent on a broad scope of
protection for its ESTs to generate revenue to continue to develop its massive
database, since it is the power of Potter's EST database as a whole in
revealing target genes that is most valuable to Big Pharma. Genetics and the
Law, supra note 6, at 566-70.
86. See Marshall, supra note 43, at 1752 (discussing Merck's Reasons for
opposing patenting genetic data). Merck's Vice President of Research Strategy
Worldwide, Alan Williamson, comments that "Merck opposes patenting
genetic data because it 'noticed that royalty claims were stacking up' on its
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The royalty
payments that result from
such
complex
arrangements would eliminate the incentive for companies to
proceed. 87
In addition, the intellectual property web provides
many companies an opportunity to exclude patients from access to
valuable medical breakthroughs.'
Therefore, the ideal patent
protection for patents to ESTs must seek to minimize the number
of patents covering complex medical breakthroughs.
Finally, the hypothetical gene discovery scenario reveals the
value in publication of EST sequences. Fundamental discoveries,
such as that of Mr. Gower, that utilize the disclosed invention to
improve an entire discipline, are critical to assure continuous
technological
development that promotes
further medical
breakthroughs. 9 Therefore, the ideal patent protection for patents
to ESTs must provide public access to the sequences. °
C. The Effects of Various Forms of Patent Protectionfor ESTs
Based on the objectives of patent protection for ESTs revealed
above, the PTO must award patents based on EST disclosures
with a limited scope of protection, not encompassing sequences
outside the EST, to assure the best balance of these objectives.
First, an EST patent of narrow scope would not allow the EST

products." Id. See also Collins et al., supra note 43, at 1581 (discussing the
discovery of large numbers of SNPs and indicating that "[a]lthough some of
these private collections [of SNPs] may be 'publicly available,' a tangled web of
restrictive intellectual property attachments might well arise, inhibiting many
researchers from using these powerful tools.").
87. See supra note 86 and accompanying text for a discussion of the
possible tangled web of intellectual property for genomic discoveries that could
result in high royalty payments for companies that market medical products.
88. A patent grants an inventor the right to exclude others from making or
selling his product. 35 U.S.C. § 154(a)(1) (1984). In many cases, owners of
patent rights license the right to sell their invention to others for reasonable
royalties because of the revenue provided. Thorner, supra note 55, at 1026.
89. See, e.g., Philip H. Abelson, Science and Technology Policy; Editorial,
267 SCIENCE 435 (1995) (giving an example of how a basic research discovery
has profoundly effected biotech and has started to impact medical products);
H. A. Ehrlich et al., Recent Advances in the Polymerase Chain Reaction, 252
SCIENCE 1643 (stating how polymerase chain reaction is used in the discovery
of ESTs).
90. Publication of EST sequences will occur if patents are granted on these
sequences because all patents are published. 37 C.F.R. § 1.11 (1997). Public
access to EST sequences also occurs through public disclosure of those
sequences. See supra note 39 for a discussion of public EST databases. When
all of these observations concerning the discovery and development of human
genomic information are considered, the optimal scenario for intellectual
property protection of ESTs is one which promotes the establishment and
expansion of EST libraries, promotes public disclosure of information to
facilitate the development of new technologies, and minimizes the intellectual
property web associated with medical breakthroughs.
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claim to encompass a medical product based on an entire gene,
thereby reducing the licensing burden on companies that market
such products." However, the patent protection would allow EST
owners to prohibit others from making or using the EST." Second,
awarding patents on ESTs, unlike protecting them as trade
secrets, discloses ESTs to the public where they can be freely used
by basic researchers and licensed by private institutions. 3
Furthermore, to satisfy the best-mode requirement for EST
specifications, inventors can reveal important information related
to the EST, including tissue distribution and similarities to
segments of known proteins.9 4 Third, awarding patent protection

to ESTs, unlike disclosing ESTs to the public without seeking
patent protection, provides incentive to genomics companies to
continue discovering ESTs by ensuring that a market for licensing
access to EST databases exists.99
D. The CAFC is Likely to InvalidateBroad Claims Based on EST
Disclosures
Based on recent precedent, the CAFC is likely to invalidate
broad claims based on EST disclosures in view of the writtendescription requirement 6
In Regents of the University of
California v. Eli Lilly and Fiers v. Revel, the CAFC held that the
patent must disclose the DNA sequence of an entire protein-coding
91. See, e.g., Genetics and the Law, supra note 6 (discussing the pros and
cons of the types of protection utilized to protect ESTs). Genes have been
discovered by several groups apparently without the use of an EST, even
though an EST encoding part of that gene had been disclosed in a public
database. Id. An analysis of our hypothetical development cycle also
illustrates this conclusion. Bailey's discovered and developed the Uncle Billy
gene without using the C0292 EST. Therefore, gene therapy using the Uncle
Billy gene would not infringe a C0292 patent with a limited scope of
protection, limited to the C0292 EST.
92. 35 U.S.C. § 154(a)(1). Basic patent protection, giving the owner of the
patent the right to exclude others from making or using the inventions, would
apply to EST patents, as they apply to any other patented invention. Id.
Therefore, if another scientist uses a patented EST to discover a full-length
gene, that scientist has infringed the EST patent. Id.
93. See supra note 79 for a discussion of publication of U.S. patents.
94. 35 U.S.C. § 112 (1975).
95. See Genetics and the Law, supra note 6, at 565-70. Pharmaceutical
companies have signed large licensing agreements with genomics companies
and Universities to obtain access to EST databases. Id. It could be argued
that the willingness of the pharmaceutical giant Merck to invest a large sum
of money to establish a public EST database is evidence that EST discoveries
by genomics companies will be supported even if those discoveries are released
to the public domain. Id. However, the investment by Merck to develop the
public EST database is only a fraction of the investment by other companies to
gain access to the private databases. Id. at 569-70.
96. Regents, 119 F.3d at 1566-69; Fiers, 984 F.2d at 1166-71.
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DNA segment to meet the written-description requirement for
claims that encompass that DNA entire segment.97 Similarly, the
CAFC will likely hold that the disclosure of an EST, a partial DNA
sequence of a gene, does not meet the written-description
requirement for claims encompassing an entire protein-coding
DNA segment.98 An EST is similar to the rat insulin cDNA
disclosed in the patent in suit in Regents in that it is a useful
probe for isolating a full-length human cDNA, but does not reveal
the complete DNA sequence of that cDNA.9
E. FactualVariations on EST Discoveries and the WrittenDescriptionRequirement'00
It could be argued that the disclosure of an EST sequence,
and the deposit of an apparently full-length cDNA that contains
the EST, meet the written-description requirement for the entire
cDNA.'0 ' This argument fails, however, even where an inventor
discloses dual ESTs apparently representing both ends of a
cDNA.'0 A partial DNA sequence disclosure does not precisely
define the complete DNA sequence, "such as by structure, formula,
chemical name, or physical properties."" 3
This conclusion is the result of several considerations. First,
based on a partial sequence determination, an inventor cannot
unequivocally demonstrate that he has deposited a complete
cDNA.1' Therefore, the inventor would not prove to the Patent
Examiner that he or she is in possession of the entire claimed
invention. 10 Second, if the PTO awards claims encompassing an
97. Regents, 119 F.3d at 1566-69; Fiers, 984 F.2d at 1166-71.
98. Regents, 119 F.3d at 1566-69; Fiers, 984 F.2d at 1166-71.
99. Regents 119 F.3d at 1567.
100. See Adams et al., supra note 25 and sources cited in note 40 (showing
that it is difficult to make generalizations for ESTs because of the almost
unlimited factual variations surrounding their discoveries).
101. See Fiers, 984 F.2d at 1169-70 (agreeing with the PTO Board in holding
that a particular segment of DNA was not described because it "did not
disclose the nucleotide sequence or 'an intact complete gene'").
102. See supra note 40 and accompanying text for a discussion of EST
databases that have been generated containing ESTs from both ends of the
insert.
103. Fiers, 984 F.2d at 1171.
104. See generally Adams et al., supra note 25 (indicating that partial
cDNAs were favored over complete cDNAs and indicating the average length
of an EST was far less than the average size of a complete cDNA). Even where
mRNA size determinations appear to match the cDNA insert size, it cannot be
determined with certainty that the cDNA is complete until it is sequenced.
See, e.g., Papadopoulos et al., supra note 30 (exemplifying the use of a
comparison of mRNA size to insert size to determine whether an entire insert
is present).
105. See Fiers, 984 F.2d at 1169-70 (indicating that an inventor must possess
the entire gene to possess the entire claimed invention, if the claims
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entire cDNA based on the disclosure of only a portion of the cDNA,
as provided by an EST, the possibility remains that a multitude of
patents claiming an identical cDNA will be awarded, which
violates patent laws."0 Third, if claimed DNA sequences are not
disclosed in their entirety, it becomes too cumbersome for
inventors to determine the novelty of DNA sequences they discover
since they would have to individually analyze a plethora of
segments, which is not feasible. Finally, where an inventor
apparently discovers the sequence from an entire cDNA based on
combining overlapping EST sequences from independent cDNA
clones, the written-description requirement is not met because the
inventor has not proven that he possesses the complete DNA
segment."'
F. Is the Written-DescriptionRequirement Met for an EST DNA
Segment?
Some experts may argue that a specification that discloses an
EST does not satisfy the written-description requirement, even for
claims limited to only the EST, because of the inaccuracy of the
DNA sequence determination of the EST, or because the inventor
has not isolated the EST DNA segment away from other DNA
segments on the cDNA. However, the reported accuracy for ESTs
appears to be sufficient to provide warning to potential infringing
parties of related sequences that may warrant further analysis. 0 8
As to the isolation of the EST insert, although it is likely a
DNA deposit associated with an EST disclosure contains cDNA
segments in addition to the EST, with modern methods and a
deposit of a DNA sequence containing the EST, one of ordinary
skill in the art could easily isolate the EST DNA segment away
from the remainder of the cDNA segment.0 9 Since it appears the
written-description requirement is met for the ESTs themselves as
long as a deposit is made, if two ESTs from the same cDNA reveal
the complete sequence of a cDNA, claims encompassing the entire
cDNA would be supported.
encompass that gene).

106. 35 U.S.C. § 101 (1975). For many ESTs in the public databases, even
where the ESTs were generated from the ends of a cDNA, many different pairs
of flanking ESTs can be found for one gene. Id. This multiplicity in ESTs
generated from the ends derived from the same gene results from alternate
splicing of the gene and incomplete cDNA formation during cDNA synthesis.
Id. This is true even in the situation where a scientist synthesized the cDNAs
starting at one known end of the gene by using poly dT primers. Id.
107. See supra note 104 for a discussion of the difficulties in determining
whether a cDNA is complete from the disclosure of an EST from that cDNA.
108. See supra note 35 for a discussion of the reduced DNA sequence
accuracy for ESTs compared to traditional sequencing methods.
109. LEWIN, supra note 16, at 645.
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G. Written-DescriptionRequirement Applied to Other DNA
Fragments Derived from the Human Genome

The arguments relating to the limited scope of patent
protection for ESTs can also be applied to other inventions derived
from the human genome, such as isolated complete cDNAs and
SNPs. Repetitive and rapid methods have been developed for
isolating and sequencing various DNA segments, including
complete cDNAs and SNPs."' Therefore, considerations regarding
the optimal protection of these discoveries are similar to those
analyzed above for ESTs."' However, the risk of such a limited
scope, especially when considering patents based on disclosures
containing a thorough characterization of an entire cDNA, is that
the resultant claims provide little economic value." 2 A company
will not spend large sums of money to develop and characterize a
blockbuster gene unless there is some assurance that a skilled
artisan cannot easily design around a claim to the gene."' In
Regents, the CAFC held that inventors can obtain broad patent
protection for DNA segments, and described in general terms the
characterization necessary to support such broad claims." 4 Based
on this precedent, inventors can obtain broad patent protection of
a DNA segment if a proper characterization of that segment is
disclosed."'

110. See Collins et al., supra note 43, at 1580-81 (discussing the methods
that are being developed for generating large quantities of SNPs at very low
cost); Debbie Strickland, Invitrogen Launches Rapid Cloning System, 1998
BIOWORLD TODAY 2, 2 (discussing a new technology which allows the rapid
and semi-automated cloning and expression of DNA segments which contain
entire protein-coding regions of genes).
111. See supra note 91 and associated text for a discussion of the optimal
intellectual property protection for ESTs.
112. See Kenneth G. Kahine, Going Beyond the Native: ProtectingDNA and
Protein Patents, 15 BIOTECH 183, 183-84 (1997) (discussing the ease of
designing around narrow patents relating to recombinant DNA molecules).
113. See Rachel Nowak, Breast Cancer Gene Offers Surprises, Includes
Related Article on the Competition to Find the Gene, 265 SCIENCE 1796 (1994)
(discussing the four year race that took place between researchers to isolate
the BRCA 1 gene, which is involved with many inherited breast cancers).
114. See supra note 78 and accompanying text for a discussion of the
guidelines of the CAFC in Regents for obtaining a broad scope of protection for
Based on this precedent, in our
a patent covering DNA segments.
hypothetical situation, since Bailey's extensively characterized the Uncle Billy
gene, they could obtain broad protection for this gene that would make it
virtually impossible for a competitor to design around. Furthermore, Bailey's
could apply the .doctrine of equivalents to expand its protection even further.
CHISUM, supra note 44, § 18.01.
115. Regents, 119 F.3d at 1569.
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IV. PROPOSAL FOR A NEW DIMINISHED PATENT TYPE FOR CERTAIN
INVENTIONS DERIVED FROM THE HUMAN GENOME

Based on the preceding analysis, the following proposal is
offered.
Section A suggests minimum requirements for
characterization of DNA segments to assure that patents claiming
these sequences meet the written-description requirement of 35
U.S.C § 112. Section B sets forth possible statutory changes to
reduce the term and examination process for patents awarded to
minimally-characterized segments of DNA derived from the
human genome, including ESTs. Section C recommends that the
disclosure of an entire DNA sequence of a gene by overlapping
ESTs does not make the entire cDNA obvious under 35 U.S.C. §
103.
A. DisclosureRequirements for Patents which Claim DNA
Segments Derived from the Human Genome"0
The PTO should require that to meet the written-description
requirement for a DNA segment, an inventor must determine the
DNA sequence of the entire claimed DNA segment, and if a
relatively inaccurate DNA sequencing method was used, must
deposit a recombinant DNA vector containing the DNA segment in
a public depository."7 As discussed previously, the requirement for
116. It is difficult to make general proposals related to ESTs because of the
many factual possibilities surrounding EST disclosures, some of which were
illustrated in previous sections. Compare Adams et al., supra note 25, at 1652

with Boguski & Schuler, supra note 35, at 369. Adams described a procedure
for generating ESTs by randomly priming partial cDNAs. Adams et al., supra
note 25, at 1652. Boguski & Schuler, described an approach utilizing dual
ESTs representing both ends of a potentially full-length cDNA. Boguski &
Schuler, supra note 35, at 369. However, the proposal attempts to set
minimum requirements and to analyze a few of the variables associated with
EST disclosures.
117. The requirements are consistent with CAFC precedent regarding
inventions of segments of DNA in requiring that the entire DNA sequence of
the DNA fragment be described. See supra note 61 and accompanying text for
a discussion of the written-description requirements and DNA segments. The
CAFC holds that the complete DNA sequence is required to assure that the
inventor describes the invention sufficiently to permit a skilled artisan to
understand the full invention and to assure that the inventor was in
possession of the invention at the time of filing the patent application. Fiers v.
Revel, 984 F.2d 1164, 1170 (Fed. Cir. 1993). In Fiers, the CAFC agreed with
the PTO Board in holding that since one of the possible inventors did not
reveal the DNA sequence of the invention he did not "reasonably convey to the
artisan that the inventor had possession at that time of the ...later claimed
subject matter." Id. In addition, the complete DNA sequence of a claimed
invention might be required even where deposits of the DNA are made
available to the general public so that an inventor is not required to
experiment with potentially tens or hundreds of thousands of deposited DNA
segments to determine whether a DNA segment is novel. Furthermore,
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a determination of the DNA sequence for the entire claimed DNA
segment is consistent with CAFC precedent regarding patents to
DNA segments. This assures that an unreasonable amount of
experimentation relating to characterizing deposited DNA
segments is not necessary to allow a determination of novelty for
other DNA segments, and decreases the number of patents
encompassing identical human genome-derived components of
future medical products."" A deposit of the DNA segment is
necessary to meet the written-description requirement, when a
relatively inaccurate DNA sequencing method is used to sequence
the segment, to provide assurance that the inventor is in
possession of the DNA segment, to make the DNA segment readily
available to those skilled in the art, and to allow a confirmation of
Based on these
the DNA sequence if a dispute arises. "'
requirements, the PTO must not grant broad patent protection
that encompasses entire cDNAs or genes based on the disclosure of
one or more ESTs within that cDNA or gene. This should hold
even where an inventor deposits a DNA segment that appears to,
but has not been proven to, contain the entire cDNA."'

refusing to grant patents to an entire cDNA based on an EST disclosure
eliminates the possibility that several patents to identical complete proteincoding sequences would be granted, where independent disclosures are made
of two unique ESTs derived from the same cDNA.
118. See supra note 61 and accompanying text for a discussion of CAFC
requirements for DNA segments in meeting the written-description
requirement. See also supra note 86 and accompanying text for a discussion of
the tangled web of intellectual property that could result from patents to
ESTs.
119. In requiring the deposit of the DNA sequence to meet the writtendescription requirement, the proposal touches on an issue not yet addressed by
the CAFC with respect to the written-description requirement. However, the
CAFC held in Amgen that for the best mode requirement it is not necessary to
deposit cells containing the claimed recombinant DNA molecule with a public
cell bank. Amgen, 927 F.2d at 1211. The availability of the deposit to confirm
the DNA sequence of a patented segment is important for EST inventions
because many of these inventions utilize less-accurate rapid DNA sequencing
methods. The PTO Board of Patent Appeals and Interferences indicated in
dicta that the written description was not met for a DNA segment with
sequencing errors where the DNA segment was not deposited. Ex parte
Maizel, 27 U.S.P.Q.2d 1662, 1667 (Bd. Pat. App. & Int. 1992). See supra note
35 for a comparison of the accuracy of DNA sequencing utilized to generate for
ESTs and traditional sequencing methods.
120. The PTO should not award patents to DNA segments derived from the
human genome which incorporate "comprising" language in the claims.
Pasahow & Kumamoto, supra note 55, at C34. See supra note 56 and
associated text for a discussion of the meaning of the term "comprising" in
patent claims. Instead, these patents should be required to use "consisting of"
language in the claims. See also supra note 55 and associated text for a
discussion of the meaning of the term "consisting of" in DNA patent claims.
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B. Reduced Patent Term and Examinationfor Human DNA

Patents of limited scope should be awarded to ESTs and other
DNA segments derived from the human genome. However, there
are risks involved in awarding limited patents to ESTs based on
the inaccuracy of the sequence determination and the burden 1of
21
excessive patent protection on marketed medical products.
Furthermore, in most cases the discovery of ESTs is rapid,
requires minimal inventiveness, and has minimal practical utility
of most EST discoveries, whereas the process of examining patent
applications claiming these ESTs is time-consuming and
expensive.122

With the foregoing considerations in mind, Congress and the
biotech community must consider implementing a special patent
category for patents to human DNA segments where a medical or
industrial utility is not demonstrated.
This special patent
category would award a limited term based on a diminished
examination process. 12' For example, a five-year term can be
appropriate for these patents, although such a determination
requires considerable comment from the biotech community before
implementation."24 To minimize the resource requirements for the
121. See supra note 35 and accompanying text for a discussion of the
inaccuracy of EST sequence determinations compared to traditional sequence
determinations.
See also supra note 86 and accompanying text for a
discussion of the complex web of intellectual property that may result from
awarding nonprovisional patents based on EST disclosures.
122. See supra note 32 and accompanying text for a discussion of the
limitations of EST technology and supra note 10 for a discussion of the
burdens on the PTO of examining EST patent applications.
123. See Adler, supra note 6, at 913.
Perhaps patenting is not the optimal system when unprecedented
volumes of data about informational molecules are published. A
registration system, like copyright, might be simpler and more
affordable.
To encourage the development of other important
technologies, federal laws were enacted to create new intellectual
property systems that would protect novel plant varieties and
semiconductor chip masks. This approach might be necessary for DNA
sequence inventions.
Id. The proposed diminished category is different than the provisional type of
patent currently available in the U.S. because an examination is required to
obtain a patent under the proposed category, and all of the required parts of
the application would be required, including claims. See supra note 50 and
accompanying text for a discussion of the provisional patent application.
However, the proposed new category could be set up like a provisional
application in that it could be converted into a nonprovisional patent if, for
example, information regarding the utility of the EST related to human
disease is disclosed before the shortened term ends. Id.
124. This term determination should consider the possible delay in
marketing a medical breakthrough as a result of the owner of an EST patent
exercising his patent right to exclude others from using patented ESTs. In
addition, the term should provide enough time for a company to sufficiently
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PTO, the examination process for these patents can be
standardized, and reliance can be placed on an inventor regarding
the determination of novelty and non-obviousness. 2 ' The inventor
could establish the novelty and non-obviousness of his EST
invention by determining that no matches are contained in public
DNA databases.11 6 Furthermore, it is proposed that the utility
requirement could be met by an inventor simply by disclosing that
the DNA sequence is derived from the human genome. 12
Therefore, the examination process for EST discoveries could be
extremely diminished, thus requiring minimal PTO resources and
an accelerated approval process.1" In addition, the infringing uses
excluded by this class of inventions should include only those
associated with the physical piece of DNA and not the DNA
sequence information contained in a database. 1" This preserves
the inclusion of the DNA sequence in functional databases where
it can be used along with thousands of other sequences to identify
target genes.130
C. Obviousness of Complete cDNAs and Overlapping ESTs
The PTO and courts should hold that a complete cDNA is not
rendered obvious as the result of overlapping EST sequences."'
The rationale for this proposal is that if overlapping ESTs do not
characterize a DNA segment so as to determine its potential uses for which it

can file a standard nonprovisional application and possibly obtain the filing
date of the "diminished" patent. See, e.g., M.P.E.P. § 2133.01 (discussing
effective filing dates of continuation-in-part applications).

125. 35 U.S.C. §§ 102, 103 (1975).
126. See supra note 39 and accompanying text for a discussion of the public

databases currently available which could be used by an inventor in their
search for novelty and obviousness. For the inventor's search for novelty and
obviousness to be effective, the EST sequence must be deposited in a public
database when EST patents are issued, at the latest. Id.
127. Marshall, supra note 9, at 643.

"Several possible changes could be

made [to deal with the huge backlog of EST patents, PTO commissioner]
Lehman says. The PTO could ask DNA sequence applicants to do more
background research themselves." Id. The utility requirement is met, a
priori, by all DNA discoveries from the human genome since they can be used
as probes for a particular chromosome or set of chromosomes or as markers for
particular chromosome locations. See Adams et al., supra note 25, at 1654
(indicating that more than half of the human ESTs they identified were

mapped to certain chromosomes).
128. See supra note 10 and accompanying text for a discussion of the current
backlog in the PTO.

129. See Thorner, supra note 55, at 1024 (describing benefit of patent system
to allow those skilled in the art to use information disclosed in patent, but not
invention).
130. See supra note 43 for a discussion of functional databases.
131. This is a modification of the CAFC's reasoning that if a claimed DNA

molecule is not obvious it is not described. Regents, 119 F.3d at 1567.
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adequately describe an entire cDNA, it follows that such sequences
do not make an entire cDNA obvious. There is no single isolated
DNA molecule that includes the whole sequence. This is especially
important since the plethora of public and (apparently soon to be
patented) private EST sequences in combination may reveal the
complete DNA sequence of hundreds or thousands of complete
protein-coding regions. 132 By preserving the patentability of
sequences containing complete protein-coding regions, the PTO
and courts provide inventors a sufficient incentive to isolate and
characterize entire protein-coding segments of genes.
CONCLUSION

The risks posed by granting broad patent protection based on
EST disclosures are illustrated by considering what could happen
if Mr. Potter owns these broad patent rights. Fortunately, the
CAFC narrowly construes patent rights based on disclosures of
DNA sequences, and as a result, will likely invalidate patent
claims based on EST disclosures that contain a broad scope of
protection encompassing a gene or even an entire protein-coding
segment of a cDNA. The PTO should award narrow claims to
ESTs such that the written-description requirement that the
CAFC has established is met and the development of innovative
medical products continues. Furthermore, to establish optimal
patent protection for DNA sequences derived from the human
genome, Congress, the PTO, and the biotech community should
consider implementing a new limited patent category with a
reduced term and decreased examination scrutiny.
After Clarence, a patent attorney in his previous life, informs
George Bailey that it is unlikely the CAFC will uphold broad
patents based on EST disclosures, George is overjoyed and pleads
with Clarence to grant him another chance at life so that he can
make certain that the launch of gene therapy based on the Uncle
Billy gene is successfully completed. Remember, no inventor is a
failure who has a good patent attorney. 83 "Atta Boy, Clarence!"" 4

132. See UniGene, supra note 39 (discussing the possibility that overlapping

ESTs exist which reveal the entire DNA sequence of a cDNA).
133. See WONDERFUL LIFE, supra note 2 (including a letter from Clarence to
George: "Dear George, remember no man is a failure who has friends..
134. WONDERFUL LIFE, supra note 2.

